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Abstract
It was claimed by the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR)) in a report
to the EU-Commission that “....no risks of adverse systemic effects exist and the current use of dental amalgam
does not pose a risk of systemic disease...” [1, available from: http://ec.europa.eu/health/ph_risk/committees/
04_scenihr/docs/scenihr_o_016.pdf].
SCENIHR disregarded the toxicology of mercury and did not include most important scientific studies in their
review. But the real scientific data show that:
(a) Dental amalgam is by far the main source of human total mercury body burden. This is proven by autopsy
studies which found 2-12 times more mercury in body tissues of individuals with dental amalgam. Autopsy studies
are the most valuable and most important studies for examining the amalgam-caused mercury body burden.
(b) These autopsy studies have shown consistently that many individuals with amalgam have toxic levels of
mercury in their brains or kidneys.
(c) There is no correlation between mercury levels in blood or urine, and the levels in body tissues or the severity
of clinical symptoms. SCENIHR only relied on levels in urine or blood.
(d) The half-life of mercury in the brain can last from several years to decades, thus mercury accumulates over time
of amalgam exposure in body tissues to toxic levels. However, SCENIHR state that the half-life of mercury in the
body is only “20-90 days”.
(e) Mercury vapor is about ten times more toxic than lead on human neurons and with synergistic toxicity to other
metals.
(f) Most studies cited by SCENIHR which conclude that amalgam fillings are safe have severe methodical flaws.
Dental amalgam is the main source of mercury in
human tissues
SCENIHR (Scientific Committee on Emerging and
Newly Identified Health Risks) from the European Com-
mission claim [1]: “Exposure to mercury is difficult to
measure. The indications for mercury exposure are
therefore normally obtained by measuring mercury
levels in urine and blood of individuals.”
SCENIHR did not cite any autopsy studies, which are the
most reliable studies for assessing mercury levels intissues.
An approx. 2-5-fold increase of mercury levels in
blood and urine in living individuals with dental
amalgam as well as a 2-12 fold increase in several body
tissues was observed in deceased individuals with dental
amalgam [2-21]. Additionally, studies with animals have
confirmed the fact that dental amalgam leads to signifi-
cantly increased levels in the tissues [22-28].
According to these studies, dental amalgam is respon-
sible for at least 60-95% of mercury deposits in human
tissues. This was not acknowledged by SCENIHR.
No organic mercury compounds through dental
amalgam?
SCENIHR [1] state that “there is no evidence that bio-
transformation of amalgam derived mercury takes place
intra-orally in association with bacterial activity.” Correspondence: jm@zahnklinik.de
Department of Environmental and integrative medicine Lohnerhofstraße 2,
78467 Constance/Germany
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cury (Hg) from dental amalgam is transformed into
organic mercury compounds by microorganisms in the
human gastrointestinal tract [29-31]. Leistevuo et al.
(2001) found a three-fold increase of methylmercury
levels in saliva of individuals with dental amalgam com-
pared to individuals without amalgam, although fre-
quency and kind of fish consumption were identical in
both groups. Mercury levels in saliva exceed mercury
limits for sewage in 20% of individuals with amalgam
[30]. The form of methylmercury derived from dental
amalgam may be much more toxic (up to 20 times)
than the form of methylmercury found in fish (see sec-
tion “toxicity of mercury”).
Toxic mercury levels in vitro and in vivo
Inorganic mercury levels of 0.02 ng Hg/g (2 μlo f0 . 1
μMolar Hg in 2 ml substrate) led to the total destruc-
tion of intracellular mircrotubuli and to the degenera-
tion of axons [32]. In other experiments inorganic
mercury levels of 36 ng Hg/g (0.18 μMol Hg) led to
increased oxidative stress as a prerequisite for further
cell damage [33,34].
Mercury vapor inhalation in doses which also occur in
humans with many amalgam fillings and chewing led to
pathological changes in the brains of animals after 14
days [35,36].
No toxic mercury levels in humans through
dental amalgam?
In a recent autopsy study, it was found that individuals
with more than 12 amalgam fillings have more than 10-
times higher mercury levels in several tissues including
the brain, compared to individuals with only 0-3 amal-
gam fillings [11].
The average mercury level in the brain of EU citizens
with more than 12 amalgam fillings was 300 ng Hg/g
brain tissue [11], which is well above mercury levels pro-
ven to be toxic in vitro on neurons (0.02 -36 ng Hg/g)
(see above).
In another autopsy, individuals with more than
10 amalgams have 504 ng Hg/g in their kidney tissues
(0-2 amalgams: 54 ng Hg/g) and 83.3 ng Hg/g in the
liver (0-2 amalgams: 17.68 ng Hg/g) [5].
Mercury levels in thyroid- and pituitary glands were
55 ng Hg/g and 200 ng Hg/g respectively and again,
these levels correlates significantly with numbers of
amalgam fillings [37].
Because the levels found in these studies are only
average levels, a significant portion of individuals with
dental amalgam have more than twice (standard devia-
tion) these toxic mercury levels in their body tissues. It
is important to note that mercury levels found in sub-
cellular fractions like microsomes, mitochondria and
other cell compartments even exceed the average levels
of the brain samples analysed in these studies [38].
Toxic mercury levels in Alzheimer’s disease
The average mercury load in brain tissues of individuals
with Alzheimer`s disease was 20 to 178 ng Hg/g; in
some cases the load exceeded up to (236- 698 ng Hg/g).
In 15% of the human brain samples the mercury load
was above 100 ng Hg/g [39-41]. The average mercury
load in the pituitary gland was 400 ng Hg/g [42]. These
levels are again well far above established toxic levels
(see above).
Pathological changes, caused by mercury, in most
german human brains?
About 20% of individuals in the age group of 20 years,
50% of individuals in the age group of 50 years, and
90% of people in the age group of 85 years living in
Germany show pathological changes in their brains that
are typical for Alzheimer’s disease [43] and mercury
toxicity. This coverage of pathological brain changes
caused by very low levels of mercury in experiments
and not by low levels of other metals (like lead, iron,
aluminum, copper, manganese, chromium, cadmium)
[32,36] resembles the frequency of dental amalgam fill-
ings implanted in humans: About 80-90% of people liv-
ing in Germany have dental amalgam over decades. It
must be noted that about 30-50% of german people
above the age of 85 years have Alzheimer’s disease (AD)
and there are many hints that mercury plays the major
pathogenetic role in AD [44].
Maternal amalgam as the main source of mercury
in infant tissues
Maternal amalgam fillings lead to a significant increase
of mercury levels in fetal and infant body tissues includ-
ing the brain [6]. Furthermore, placental, fetal and infant
mercury body burden correlates with the number of
amalgam fillings of the mothers [6,45-52].
Mercury levels in amniotic fluid [53] and breast milk
[54-56] also significantly correlate with the number of
maternal amalgam fillings.
Mercury in infant tissues: Increased risk of
neurodevelopmental disorders?
Drasch et al. found mercury levels of up to 20 ng Hg/g
in German infant brain tissues which were mainly
caused by dental amalgam fillings of their mothers [6].
As described above, mercury levels of 0,02 ng Hg/g led
to degeneration of axons [32]. Furthermore, the mercury
levels found in the brains of infants whose mothers were
dental amalgam bearers are sufficient enough to inhibit
the function of the important enzyme methionin syn-
thetase [57,58]. Methionin synthetase is crucial for
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reactions the the body, including the development of the
brain, the maturation of nerve cells and the production
of neurotransmitters.
Maternal amalgam fillings also increase significantly
mercury levels in cord blood [59,60]. The risk for
delayed neurodevelopment of children was 3.58- times
increased when mercury levels in cord blood were
higher than 0.8 ng Hg/ml [61]. It is important to note
that mercury levels of 0.2 - 5 ng Hg/ml cord blood are
considered “normal” in Germany [62], thus leaving
many infants with mercury levels that may cause neuro-
developmental deficits.
No correlation between mercury in urine or blood
and in body tissues
The SCENIHR report is based on studies which have
measured mercury levels in biomarkers such as urine
for the assessment of clinical symptoms or mercury
body burden. However, the WHO states (1991) that
“Mercury typifies a “retention” toxicity and much of
the mercury taken into the body is absorbed by the
solid tissues. The amount in urine represents mer-
cury being excreted. However, the main question is
how much is being retained in the different body
tissues”.
It has been shown in experiments with animals
and men that in spite of normal or low mercury
levels in blood, hair and urine high mercury levels are
found in critical tissues such as brain and kidney
[7,13,20,22,25,28,46,63,64]. A recent study on deceased
individuals confirm that there exists no correlation
between inorganic mercury levels in urine or blood and
mercury levels in brain tissues [37].
Drasch and coauthors have shown that 64% of indivi-
duals occupationally exposed to mercury vapor and hav-
ing typical clinical signs of mercury intoxication had
urine levels of mercury below 5 μg/l, which represent
the No Observed Adverse Effect Level (NOAEL). The
same results were found for mercury levels in blood and
hair [65-67].
Paradoxical association between mercury levels in
urine and clinical symptoms
There is even a paradoxical correlation between mercury
levels in urine, blood or hair and clinical symptoms:
Subjects with highest urine levels of mercury showed
best recovery rates from neuropsychological complaints
after removing their amalgam fillings [68]. Also children
with highest mercury levels in hair showed better per-
formance in developmental tests [69]. Another study
indicates that in spite of a significantly higher exposure
to mercury in their mothers` womb autistic children
had up to 15-times lower mercury levels in their infant
hair than healthy children [46]. Furthermore, the lower
the mercury levels in infant hair, the higher was the
severity of autism [46].
Despite higher mercury body burden, a “amalgam
hypersensitivity” group showed slightly lower levels of
mercury in their saliva, blood and urine [70]. Even after
provocation with the mercury chelator DMPS, the
“amalgam hypersensitivity” group excreted in mean only
7,77 μg Hg via urine in 24 h whereas healthy amalgam
bearers excreted 12,69 μg Hg/24h [70].
Furthermore, studies confirm that the ratio of fecal
to urine excretion is 12 to 1 [13]. This proves that the
majority of excreted mercury leaves through the bilary
transport system of the liver via the fecal route. Urine
mercury therefore represents a minor excretory route
of less than 8% of mercury being excreted. Also, urine
mercury is a measure of mercury being excreted
by the kidney—not a measure of total mercury body
burden.
Safety levels for mercury?
In view of the data presented above, it is impossible to
determine any safety levels below which adverse effects
can be excluded [71]. SCENIHR used safety limits which
were deduced from studies with workers occupationally
exposed to mercury. However, these limits cannot be
applied to individuals with amalgam fillings and must be
critically evaluated:
a) Frequently, mercury exposure of workers in the
chlorine-alkali industry is used for comparison
although the simultaneous exposure to chlorine con-
siderably diminishes the absorption of mercury into
the body tissues of animals by 50-100% [72].
b) Workers exposed to mercury usually represent a
group whose mercury-exposure starts only with
adulthood (for about 8 hours a day, 5 days a week),
while amalgam bearers can be exposed to mercury
in the womb through maternal amalgam fillings dur-
ing their childhood and until death at a rate of 24
hours per day, 7 days per week.
c) Workers are a selected healthy group, while preg-
nant women, infants, children and individuals with
illnesses (such as multiple sclerosis, autoimmunity,
cancer, psychiatric diseases) do not start working at
all either due to industrial safety regulations or to
early health problems during working.
d) Despite mercury exposure below “safety limits”,
significant adverse health effects were found in most
studies in workers exposed occupationally to mer-
cury, even several years after the exposure had
ceased [73-81].
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SCENIHR state that the body half-time (of mercury) is
“20-90 days”.
Particularly in the brain, mercury has a significantly
longer half-time of more than 17 years [63,64,82-87].
Toxicity of mercury
SCENIHR did not mention the specific toxicity of mer-
cury vapor coming off dental amalgam fillings. This
should be mentioned in a risk analysis:
Mercury has been shown to be 10 times more toxic
than lead (Pb) in vitro [88-90]. Mercury is the most
toxic non-radioactive element. Mercury vapor is one of
the most toxic forms of mercury along with some of the
organic mercury compounds. This extraordinary toxicity
is also determined by the following properties:
a) Mercury is the only metal representing a volatile
gas at room temperature, which is readily absorbed
(80%) by the respiratory system.
b) Mercury vapor from amalgam penetrate into tis-
sues with great ease, because of its monopolar
atomic configuration.
c) Once inside the cells, mercury vapor is oxidized
to Hg
2+, the very toxic form of mercury which binds
covalently to thiol groups of proteins inhibiting their
biological activity.
d) Hg
2+ is more toxic than Pb
2+, Cadmium (Cd
2+)
and other metals because it has a higher affinity due
to “covalent bond” formation with thiol groups
(cysteines in proteins) causing irreversible inhibition.
Other metals form reversible bonds with proteins
and are therefore less toxic.
e) Hg
2+ does not bind tightly enough to the carboxy-
late groups of natural organic acids (natural chela-
tors like citrate) for its toxicity to be prevented.
f) Chelating agents, like EDTA, which normally inhi-
bit the toxic effect of heavy metals like lead, have no
inhibitory effect on the toxicity of mercury or may
even increase it [91,92]. Other chelating agents
(DMPS and DMSA) inhibit the toxic effect of Cd
2+
and Pb
2+, but not of Hg
2+ [93]. DMPS, DMSA or
natural chelators like vitamin C, glutathione or
alpha-lipoic acid are not able to remove mercury
from nervous tissues [94]. DMPS or DMSA may
even increase the inhibitory activity of Hg
2+ and Cd
2
+on enzymes but not of Pb
2+ [95]. Furthermore,
DMPS in animals led to an increase of mercury con-
centrations in the spinal cord [96].
The toxicity of methylmercury which is bound to
cysteine in fish seems to be far lower (only approx. 1/
20) than methylmercury compounds usually used in
experiments [97].
Furthermore, marine fish represents a significant
source of selenium and essential omega-3-fatty acids,
which are known to protect effectively against mercury
toxicity. Nevertheless, methylmercurychloride, which
proved to be more toxic than methylmercury in fish,
showed less neurotoxicity for the growing nervous sys-
tem in vivo than did mercury vapor [98].
Investigations by Drasch et al. show similar correla-
tions: The population of a goldmining area, which was
exposed to mercury vapor, showed significantly more
neurological symptoms of mercury intoxication than a
control group which mainly was exposed to methylmer-
cury from fish consumption, despite their mercury levels
in hair and plasma being higher compared to the indivi-
duals exposed to mercury vapor [65,66]. Another study
also points to smaller neurotoxicity of methymercury
from fish compared to iatrogenic mercury sources
(amalgam, thimerosal) [46]. Here, in contrast to the
numbers of dental amalgam in the mothers, no correla-
tion between maternal fish consumption during preg-
nancy and the risk of autism for their children was
found.
In summary, mercury vapor coming off dental amal-
gam or methylmercury derived from amalgam in the
gastrointestinal tract has not reacted with anything yet
and has the full toxic potential. On the other hand,
methylmercury in fish has already reacted with fish pro-
teins and other protective molecules or atoms in fish tis-
sues such as glutathione or selenium, which are
enriched in fish. Furthermore, newest studies confirm
that most individuals with dental amalgam fillings are
exposed to toxic mercury levels [99,100].
Synergistic toxicity of mercury to lead (Pb)
Some scientists try to argue that results gained by ani-
mal or cell testing are overestimated and not compar-
able to the situation of the human body. However, in
contrast to test animals in experiments, humans are
exposed to many other toxins simultaneously, thus the
effects add up or are even synergistic [101,102]. For
example, it has been proven that the combination of the
Lethal Dose 1% of mercury (LD1Hg) together with the
LD1 of lead (Pb) results in the death of all animals, so
the following toxicological equation can be assumed:
LD1 (Hg) + LD1 (Pb) = LD 100 [101].
In this context, it must be considered that modern
humans have more mercury and between 10-1,000-
times more lead in their body tissues than ancient
humans.
In other experiments, the addition of aluminumhydr-
oxide (often in vaccines), antibiotics, thimerosal (some-
times in vaccines) and testosterone increased the
toxicity of mercury [108,109]. The synergistic toxicity of
testosterone explain the observation, that much more
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lateral sclerosis.
No adverse effects through dental amalgam?
SCENIHR states “It is generally concluded that no
increased risk on adverse systemic effects exists and we
do not consider that the current use of dental amalgam
poses a risk of systemic disease” and “....some local
adverse effects are occasionally seen with dental amal-
gam fillings, but the incidence is low and normally read-
ily managed”
SCENIHR has neglected numerous scientific studies
which find significant adverse health effects from dental
amalgam:
Cytotoxicity of amalgam in comparison to
composites
SCENIHR compare the toxicity of amalgam with com-
posites. However, in most experiments, even inorganic
mercury, which is much less toxic than mercury vapor
(because inorganic mercury is not able to penetrate
easily into the cells), was proven to be much more toxic
than any composite compound: Mercury was shown to
be 100-800- fold more toxic than composite compo-
nents for human cells [110-114].
Genotoxicity, oxidative stress, cancer
Dental amalgam fillings have been found to cause DNA
damage in human blood cells. [115]. Even low levels of
inorganic mercury lead to significant DNA damage in
human tissue cells and lymphocytes [116]. This effect,
which trigger cancer, has been found with mercury
levels below those normally causing cytotoxicity and cell
death. Furthermore, aberrations of chromosomes can be
provoked by amalgam in cell cultures [117]. Amalgam
bearers show significantly increased oxidative stress in
saliva [118,119] and blood [120,121]. The increase of
oxidative stress correlates with the numbers of amalgam
fillings. Mercury levels normally seen in tissues of indivi-
duals with amalgam fillings lead to increased oxidative
stress and reduction of glutathione levels, thus inducing
cellular damage [33,34]. Significantly elevated mercury
levels have also been observed in breast cancer tissues
[ 1 2 2 ] .M e r c u r yd e p o s i t e di nt h et i s s u ei sm o s t l yb o u n d
to selenium, which means that the this selenium is no
longer available for the body. Therefore, amalgam may
aggravate a latent deficiency of selenium, particularly in
countries with suboptimal selenium supply (e.g. in Cen-
tral Europe) [123,124].
Antibiotic resistance
It has been shown that mercury from dental amalgam
can induce mercury resistant bacteria [125-127]. This
leads to a general antibiotic resistance in oral bacteria
and in other body sites [127], which is particularly true
w h e nt h ea n t i b i o t i cr e s i s t a n c eg e n e sa r ec o n t a i n e d
within the same mobile element as the mercury resis-
tance operon [128,129]. Mercury resistance is common
in human oral bacteria [130,131]. Monkeys with dental
amalgam also showed an increase in antibiotic resistant
bacteria in their stools [127,132].
Penetration of amalgam in tooth bone and jaw
Experiments on monkeys and sheep have shown that
mercury from amalgam penetrates easily into the dentin
r o o t sa sw e l la si n t ot h ej a wb o n e[ 2 5 , 2 6 ] .T h ef a c tt h a t
this was also shown for humans [133] confirms an alter-
native route of mercury exposure caused by amalgam.
Skin
There is a correlation between atopic eczema and IgE-
levels and the body burden of mercury [134]. Amalgam
fillings can induce lichenoid reactions [135-139]. In
more than 90% of the cases, these lesions have been
found to recover upon removal of amalgam, no matter
whether an allergy patch test was positive or not. Gran-
ulomatosis improved likewise [140]. Also, other forms of
dermatitis seem to be related to dental amalgams
[141,142].
Autoimmune disorders and mercury
hypersensitivity
Constant low-dose mercury exposure, as is common in
amalgam bearers, has been considered a possible cause
for certain autoimmune disease s ,e . g .m u l t i p l es c l e r o s i s ,
rheumatoid arthritis or systemic lupus erythematosus
(SLE) [135,143-152]. These effects occur with exposure
below mercury safety limits [153]. Recent research has
shown that mercury and ethylmercury have the ability
to inhibit the first step (phagocytosis) in the innate and
acquired immune response of humans at very low levels
[154]. This shows that mercury exposures quite below
the average exposure through amalgam exposure can
cause disruption of the immune system at all ages.
Only “rare cases of proven allergic reactions"?
SCENIHR only accept the “proof” of allergic reactions to
amalgam, which is a positive cutaneous patch test. How-
ever, it has been shown that in more than 90% of the
cases with mucosal reactions these lesions have been
found to recover by removal of amalgam, no matter
whether a cutaneous patch test was positive or not
[137,139,140]. Therefore the relevance of the cutaneous
patch test in detecting sensitivity or allergy to mercury
implanted in the oral cavity without any epicutaneous
contact has been severely questioned [155].
The results with another validated test system
reveal that there are more than just “rare cases” with
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[148,150,152,156-162].
There may also be a correlation between atopic
eczema, IgE-levels and the body burden of mercury,
which is also not detected by means of cutaneous patch
tests [134].
Because mercury from maternal dental amalgam is
one of the main sources of mercury body burden in
fetal and infant tissues, postnatal atopic eczema disap-
pear after mercury detoxification of the infants [163].
Heart diseases
Mercury may cause hypertension and myocardial infarc-
tion [164].
Significant mercury accumulation (22,000 times higher
than controls) has been found in heart tissues with a
form of heart insufficiency [165].
Urinary system
SCENIHR cited only one review performed by a dentist
and published in a dental trade journal [166] as well as
5-7 year studies on initially healthy children, also per-
formed mainly by dentists, to back up their argument
that “there is no evidence that dental amalgam fillings
affect kidney function in humans”. However, there are
many other studies suggesting quite the opposite:
In animal experiments, an impairment of renal func-
tions due to amalgam fillings has been observed
[23,146,167]. Humans with amalgam fillings show more
signs of tubular and glomerular damage when compared
to individuals without dental amalgams [15]. The fre-
quently mentioned children amalgam trial study found
first signs of kidney damage (microalbuminuria) [168]
even after only 5 years of amalgam exposure.
Alzheimer’s disease (AD)
SCENIHR questioned that mercury may contribute to
the development of AD. As a proof of this statement
they cited only one study [41] published in the trade
journal of the world-wide leading American Dental
Association (ADA) [102]. In contrast, other studies have
shown that mercury play a major pathogenetic role in
AD [108,109,169,170]. A new systematic analysis of the
literature regarding the role of mercury in AD found a
significant association [124].
Parkinson’s disease (PD)
Heavy metals have long been suspected to be a cause of
PD, with several studies showing a relation, including
epidemiological studies [171-180]. Elemental mercury
has induced PD [175], and in a case report, the condi-
tion of PD substantially improved after treatment with a
mercury chelator [173] and remained unchanged during
a 5-year follow-up period [173]. In another study,
significantly elevated blood mercury levels were found
in 13 of 14 patients with PD compared to healthy con-
trols [172]. This supports the conclusion of a previous
study which found a correlation between blood mercury
levels and PD [176]. Another study found significantly
higher amalgam exposure in individuals with PD com-
pared to healthy controls [179].
Adverse health effects in dental staff?
SCENIHR state that “the incidence of reported adverse
effects [in dental staff and dentists] is very low”.
A simple literature research reveals quite the opposite:
Dentists working with amalgam have an increased mer-
cury exposure [17,181,182]. In most studies available,
mercury exposure in dental clinics resulted in significant
adverse health effects in dental workers. In some studies,
the clinical outcome was not correlated with mercury
levels in urine or blood, and some authors falsely con-
cluded that mercury was therefore not the cause of the
adverse effects. However, this is not scientific since
urine- or blood mercury levels did not correlate with tis-
sue levels (see above). Lindbohm et al. (2007) found a
two-fold increased risk for miscarriage through occupa-
tional exposure to mercury (OR 2,0; 95% CI 1,0- 4,1).
The effect from mercury exposure was stronger than
from exposure to acrylate compounds, disinfectants or
organic solvents [199].
Even 30 years after cessation of mercury exposure,
dental nurses showed significant adverse health effects
[200]. In spite of the fact that 85% of the dentists and
dental technicians tested showed mercury related toxici-
ties in both behavior and physiological parameters, and
15% showed increased mercury induced neurological
deficits with polymorphism of the CPOX4 gene
[186,188,201], SCENIHR still maintain that amalgams
do not cause any significant medical problems in dental
workers, because urine and blood levels are below
“safety limits”.
Infertility
SCENIHR stated that “There is no evidence of any asso-
ciation between amalgam restorations and either male
or female fertility or obstetric parameters”. As a proof of
this statement, SCENIHR cited just one study, which
examines only semen parameters in men. However,
other studies point to the opposite direction, especially
when examining women:
Female dental assistants exposed to amalgam showed
a higher rate of infertility [198]. Women with more
amalgam fillings or increased mercury levels in urine
(after mobilization with DMPS) had a higher incidence
of infertility [202-204]. Heavy metal detoxification led to
spontaneous pregnancies in a considerable part of the
infertile patients [203]. Exposure to mercury also lead to
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which is often cited as a proof that mercury exposure
in dental clinics does not cause infertility suffers from
methodological flaws insofar as only women were
included who had already given birth to at least
one child. Women without children were excluded.
Such a study certainly cannot answer the question if
working with amalgam leads to infertility or not.
Moreover, the exposure time to amalgam was not cal-
culated and thus not included as a covariate into the
study.
Multiple Sclerosis (MS)
A 7,5-fold increased level of mercury was found in the
cerebrospinal fluid (CSF) of MS patients [208]. It would
be difficult to speculate that the presence of this
increase in the CSF would not at least exacerbate the
problems associated with MS or any other neurological
disease. The prevalence of MS has been shown to be
correlated with the prevalence of caries [209,210] and
the prevalence of amalgam [211,212]. Several MS epi-
demics occurred after acute exposure to mercury vapor
or lead [213]. In animal models inorganic mercury
caused a loss of Schwann cells which build the myelin
sheaths and stabilize the axons of neurons [214]. Auto-
immune pathogenesis, including antibodies against mye-
lin basic protein (MBP), can be provoked by mercury
and by other heavy metals [148].
MS patients who had their amalgam fillings removed
showed fewer depressions, less aggression and less psy-
chotic and compulsory behaviors when compared to a
group of MS patients with amalgam fillings [215]. They
also had significantly lower levels of mercury in blood
[216]. After amalgam removal, pathological oligoclonal
bands in the CSF disappeared in MS patients [217].
Removal of dental amalgam also led to a recovery in a
significant proportion of MS patients [147]. A retrospec-
tive study on 20,000 military individuals revealed a sig-
nificantly higher risk for MS in individuals with more
amalgam fillings [218]. This risk was underestimated,
because the study cohort which was selected by means
of medical examination consisted exclusively of indivi-
duals with good health at the time of joining the mili-
tary [218]. Another problem occurring in some studies
is the absence of documentation of the dental status
before or at the time of the onset of multiple sclerosis.
In spite of these limitations [219] a reanalysis found a
3.9- fold increased risk for multiple sclerosis in indivi-
duals with amalgam compared to individuals with no
amalgam. A recent systematic review also found an
increased risk for MS caused by dental amalgam in
spite of the fact that most studies did not use proper
amalgam-free controls [220].
Amyotrophic Lateral Sclerosis (ALS)
SCENIHR state that “there is no evidence for a relation-
ship between Amyotrophic Lateral Sclerosis (ALS) and
mercury”
In contrast to the statement of SCENIHR, there are
many studies which suggest that mercury may play a
pathogenetic role in ALS:
Mercury vapor is absorbed by motor neurons [221]
where it leads to increased oxidative stress. In experi-
ments, mercury vapor was found to promote motor
neuron diseases such as ALS [222-226]. It was proofed
that mercury enhances glutamate toxicity in neurons,
which is one factor in ALS. Case reports show a correla-
tion between accidental mercury exposure and ALS
[227,228]. There is a reported case of a Swedish woman
with more than 34 amalgam fillings who suffered from
ALS. After removal of these fillings she recovered [229].
A retrospective study reported a statistically significant
association between an increased number of amalgam
fillings and the risk of motor neuron diseases [218].
“Amalgam disease” and markers of sensitivity
Among the most frequently reported symptoms due to
amalgam fillings are: Chronic fatigue, headache,
migraine, increased susceptibility to infections, muscle
pain, lack of concentration, digestion disorders, sleeping
disorders, low memory capacity, joint pain, depression,
heart sensations, vegetative disregulation, mood disor-
ders and many more [161,215,216,230-234].
Until recently it was not possible to differentiate
between „amalgam-sensitive” and „amalgam-resistant”
persons by their mercury levels in blood or urine or an
epicutaneous test (patch test) [9,21]. However, it could
be shown that subjects could react to a mercury patch
test with psychosomatic complaints, although there was
no allergic reaction of the skin [235]. In addition, neu-
trophil granulocytes in amalgam-sensitive subjects react
differently compared to those in amalgam-resistant sub-
jects [236] and different activities of the superoxide dis-
mutase could be found [237].
Increased susceptibility to mercury and amalgam
SCENIHR did not mentioned any susceptibility para-
meters which make a significant proportion of the popu-
lation more susceptible to mercury from dental amalgam:
a) Abnormal porphyrine profiles due to mercury exposure
It is known that mercury exposure leads to aberrant
urine porphyrine profiles in dentists [238] and autistic
children and that this aberrancy was reversed by treating
these children with a mercury chelator [239-241].
A genetic polymorphism of coproporphyrinoxidase
(CPOX4) [188,201] leads to increased susceptibility to
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complaints [242].
The critical question here is the effect of mercury
vapor exposure on brain porphyrine profiles since an
aberrancy in brain heme has been associated with the
inability to remove beta-amyloid protein from brain
cells, which in turn may lead to Alzheimer’s disease
[243].
It should be noted that porphyrins lead to heme, and
heme is critical for several biochemical mechanisms: (i)
heme is the oxygen carrying cofactor for haemoglobin,
(ii) heme is a critical cofactor for the P450 class of
enzymes that are responsible for detoxifying xenobiotics
from the body, (iii) heme is a necessary cofactor for one
of the complexes in the electron transport system of
mitochondria and therefore ATP-synthesis.
Therefore, mercury inhibition of heme production
could have a multitude of secondary effects causing
human complaints and illnesses.
In spite of the fact that 85% of the dentists and dental
technicians tested showed mercury related toxicities in
both behavior and physiological parameters, and 15%
showed an increase of mercury induced neurological
deficits with polymorphism of the CPOX4 gene, orga-
nized dentistry and SCENIHR still maintain that amal-
gams do not cause any significant medical problems
because the urine and blood levels are below safety
limits.
b) Brain derived neurotrophic factor
Another genetic polymorphism of the brain derived
neurotrophic factor (BNDF) increases also the suscept-
ibility to very low level mercury exposure [186,187].
c) Apolipoprotein E diversity
It could be shown that amalgam sensitive persons are
significantly more likely to be carriers of the apolipopro-
tein E4-allel (APO-E4) than symptom free controls and
that they are less likely to carry the APO-E2 [231,234].
APO-E4 is known to be the major genetic risk factor for
Alzheimer’s disease, whereas APO-E2 decreases the risk.
It has been postulated that this is due to the difference
in capacity to remove heavy metals from the cerebrosp-
inal fluid [44,92,102,124,231,234,244]. APO-E2 possesses
two cysteines with metal binding sulfhydryl-groups
whereas APO-E4 does not have any cysteine residues.
d) Glutathione metabolism
Reduced glutathione (GSH) is the main natural chelator
for heavy metals in the body due to its sulfhydryl-con-
taining cysteine. Only mercury, which is bound to glu-
tathione (or selenium), is capable of leaving the body via
urine or biliary excretion. Thus, a high level of glu-
tathione is crucial for mercury metabolism. It has been
described that polymorphisms in genes leading to
impaired GSH production cause higher retention of
inorganic and organic mercury in the body. Other fac-
tors which may increase susceptibility to low dose mer-
c u r ye x p o s u r e ,e . g .l o wl e v e l so fs e l e n i u m ,a b n o r m a l
reaction of neutrophil granulocytes, activity of super
oxide dismutase, D4-receptor positive methionine
synthetase and impaired methionine transulfuration-
and methylation pathways (about 15% of the popula-
tion), led to decreased mercury protecting agents, like S-
adenyl-methionine, cysteine, GSH and metallothionine
[44,245-247].
Improvement after removal of amalgam
Significant improvement of health and above mentioned
diseases (including Multiple Sclerosis and other autoim-
mune diseases) have been reported after amalgam
removal (in most studies with elaborate protective
measures to minimize mercury exposure) [68,147,149,
150,159,161,217,230,233,234,248-251].
No neurodevelopmental disorders through
mercury?
SCENIHR stated that “T h e r ei sn oe v i d e n c eo fac a u s a l
relationship between dental amalgam and autism” and
“... that no link has been yet established between vac-
cines, thimerosal and autism”.
Nonetheless other authors come to opposite conclu-
sions:
“...mercury exposure altered cell number and cell
division; these impacts have been postulated as
modes of action for the observed adverse effects in
neuronal development. The potential implications of
such observations are evident when evaluated in
context with research showing that altered cell pro-
liferation and focal neuropathologic effects have
been linked with specific neurobehavioral deficits (e.
g., autism).” [252]
Cheuk and Wong (2006) in patients diagnosed with
attention-deficit hyperactivity disorder and Desoto
and Hitlan (2007) in patients diagnosed with autistic
disorders found significant elevations in blood mer-
cury levels in comparison with controls [253,254].
Adams et al. (2007) observed significant increases in
the mercury levels of baby teeth in infants with
autistic disorders in comparison with controls [255].
M e r c u r yi nb a b yt e e t hm i r r o r sm e r c u r ye x p o s u r ei n
the womb.
Recent brain pathology studies have revealed eleva-
tions in mercury levels and mercury-associated oxidative
stress markers in patients diagnosed with autistic disor-
ders. The level of mercury in the urine of autistic
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ate treatment with the mercury chelator DMSA com-
pared to healthy children [259]. Autistic children also
excrete higher concentrations of coproporphyrine which
is specific for mercury intoxication [239,240,260,261].
Detoxification of mercury with DMSA normalizes the
abnormal coproporphyrin levels in autistic children
[239,240] and led to improvement of symptoms [262].
Additionally, experimentala sw e l la se p i d e m i o l o g i c a l
studies indicate that mercury exposure is responsible for
autism or a deterioration of the disease. Prenatal expo-
sure to maternal amalgam [46,263], maternal thimerosal
[46,264] and postnatal sources (mercury from vaccines
for the child) together with a genetic sensitivity may
trigger autism. In animal experiments vaccination with
thimerosal led to symptoms similar to autism [265]. Epi-
demiological studies confirm a significant association
between low-dose mercury exposure and neurodevelop-
mental disorders [266][267][268][269][270][271]. Autis-
tic children show decreased levels of the natural
mercury chelator glutathione [272]; it is known that
mercury is capable of causing this phenomen [273]. In
some preliminary therapy studies with chelation therapy
led to improvement of symptoms [263]. The Autism
Research Institute therefore lists chelation as the most
effective therapeutic approach among 88 therapies
including 53 medications [274].
Zahir et al. (2005) described that the access of mercury
“...to man through multiple pathways air, water, food,
cosmetic products and even vaccines increase the
exposure. Fetuses and infants are more susceptible to
mercury toxicity. Mothers consuming diet containing
mercury pass the toxicant to fetuses and to infants
through breast milk. Decreased performance in the
areas of motor function and memory has been
reported among children exposed to presumably safe
mercury levels [...] Mercury has been found to be a
causative agent of various sorts of disorders, including
neurological, nephrological, immunological, cardiac,
motor, reproductive and even genetic. Recently heavy
metal mediated toxicity has been linked to diseases
like Alzheimer’s, Parkinson’s, Autism, Lupus, Amyo-
trophic lateral sclerosis, etc.”[275].
Some studies which found no associations between
mercury exposure and autism have severe methodical
flaws [245].
Severe methodical flaws in studies cited by
SCENIHR as a proof of the safety of dental
amalgam
In order to study toxic effects it is necessary to compare at
least two samples: one that was exposed to the substance
in question and one that was not. One of the main
problems in most of the amalgam studies is that the vast
majority did not incorporate a true control group that had
never been exposed to dental amalgam. Even when com-
paring samples with and without dental fillings, the sample
without dental fillings had been exposed to dental amal-
gam earlier in life. The studies cited frequently not only by
SCENIHR as a proof of the putative harmlessness of amal-
gam do not use “proper” non-amalgam control groups.
There is a prominent example to describe:
The Swedish twin study [276] actually only compared
57 twin-pairs in a co-twin analysis, and not 587 as men-
tioned by the authors and many governmental institu-
tions. As the average age of the sample was 66 years,
25% had no teeth at the time of investigation, many had
missing teeth and an unknown number had crowns
using other dental materials. Root fillings with amalgam
and amalgam fillings under crowns were not calculated.
As an allegedly “non-amalgam” group, they were com-
pared with individuals who still had teeth with amalgam
fillings. The authors found that individuals with more
amalgam fillings (which means also more own teeth)
had a better health status. It is fair to assume that indi-
viduals with few or no teeth or teeth that have been
restored with crowns or bridges had probably had dental
amalgam previously. As mercury accumulates in body
tissues, this “amalgam free group” m i g h th a v eah i g h e r
mercury body burden than the “amalgam group” with
currently existing amalgam fillings.
SCENIHR also cited Zimmer et al. (2002) as a proof of
the safety of amalgam. But this study compared two
groups exposed to amalgam (all female, one group of
patients who claimed to be suffering from symptoms
they related to their amalgam fillings and the other
group which did not report any association between
complaints and their amalgam) in terms of mercury
levels in body fluids and psychometric tests. The mean
number of amalgam fillings was identical in both
groups. They found equal mercury levels in both amal-
gam groups. Zimmer et al. (p. 210) conclude: “Thus,
mercury released from amalgam fillings was not a likely
cause of complaints reported by the amalgam sensitive
subjects” [21]. It is not clear why these authors come to
such a conclusion. Furthermore it is known from animal
experiments and pharmacological studies that indivi-
duals given equal amounts of a toxin might react differ-
ently. An example for this is that not every smoker
develops lung cancer, although smoking is now accepted
as a main cause for cancer.
“Children amalgam trials”
SCENIHR based their statement about the safety of den-
tal amalgam also on two children amalgam trials. These
studies show severe methodical flaws:
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whether mercury containing dental amalgam had
adverse neuropsychological or renal effects [277,278].
Healthy children were randomised to either amalgam or
composite surface restoration. Two children in the
amalgam group died (one possibly by committing sui-
cide) and were excluded from the study.
Power calculation (binomial - adverse event versus no
event) indicates that psychological illness, having preva-
lence of 6.7% in the composite-treated children, would
have to have had a prevalence of at least 14.5% in the
amalgam group to have an 80% chance of being proven
statistically (observed was 9.0%). Similarly for neurologi-
cal illness, observed prevalences in the composite group
(0.4% composite, 1.5% amalgam) would have needed at
least 4.5% prevalence in the amalgam group to be signif-
icant. From the authors it was concluded that “there is
no reason to discontinue use of mercury amalgam”
[277] and that “dental amalgam [...] emits small amounts
of mercury vapor” [278].
The first conclusion is a classic error: Due to its lack
of power, the study provides false reassurance that mer-
cury is ‘safe’. To effectively evaluate the effect sizes seen,
the trial should have been much larger (1500-2500/
group).
Urine porphyrin profiles and markers of oxidative
stress, which are elevated in individuals with dental
amalgam [19,119] were not measured. Also, genetic
polymorphism, which increase the susceptibility to mer-
cury, like BDNF-Polymorphism [186,188] and Glu-
tathion-S-Transferase gene polymorphism [279] were
not measured either. Furthermore, the real exposure
level of mercury (mercury vapor emitted in the oral cav-
ity) was not determined, which questions the ethics of
such a study. Research has demonstrated that the emis-
sion of mercury vapor was much higher than what has
been “estimated” by dentists. Chew et al. (1991) showed
that 43.5 microgram/cm
2/day mercury was released
from a “non-mercury releasing amalgam” and this
remained constant over the study period of 2 years
[280].
Mean mercury urine levels were significantly higher in
the amalgam groups [277,278], although in years 3 to 7
the levels of mercury in the urine of the amalgam
bearers continuously dropped until they approached the
levels of the amalgam free children [278]. But restorative
treatment was used in years 6 and 7, which should have
increased or at least maintained the urine mercury
levels. This needed explaining. In the Chew study above
[280], the amount of mercury released was steady for
2 years (the length of the study). It is known that amal-
gam do not stop releasing mercury vapor within 7 years.
The question therefore is what the drop was caused by
after year 2? Urine mercury levels are a measure of the
amount of mercury being excreted via this route.
Therefore, after two years of mercury exposure the
route of kidney excretion of mercury appears to be
becoming less effective. This is consistent with the well-
known fact that increased mercury exposure inhibits its
own excretion. It has been published and verified that
over 90% of mercury excreted by humans leaves through
the biliary transport system of the liver and is excreted
in the feces, not in the urine [13]. The conclusion of
Bellinger et al. [277] that “t h e r ei sn or e a s o nt od i s c o n -
tinue use of mercury amalgam” is amazing, because pos-
sible adverse effects may need more than five years of
mercury exposure to develop. If mercury is involved in
the pathogenesis of Alzheimer’s disease, the disease may
need up to 50 years to be diagnosed clinically [44].
One of the included criteria for the two studies was
“no interfering health conditions” including neurodeve-
lopmental disorders. The Centers for Disease Control
and Prevention (CDC) in Atlanta (USA) reports that 1
in 6 American children have a neurodevelopmental dis-
order. However, above mentined papers conclude that
amalgams should remain a viable clinical option in den-
tal restorative treatment [278] and they did not exclude
use on children with neurodevelopmental disorders -
exactly the type of child, however, which they excluded
from their studies. As mercury exposure during preg-
nancy may be the prime cause of neurodevelopmental
disorders [46,61,245], this conclusion from the children
amalgam is unsafe for the public.
Amalgam for mercury pollution
There has been an alarmingly increase of mercury in
our environment [281] and human bodies [282] over the
last decades. The UNEP reports on a 3-5 fold increase
over the last 25 years [281].
In the European Union (EU) the usage of amalgam
amounts to 120 tons yearly. Dentists are the 2
nd largest
user group in the EU [283,284].
Recent calculations done by Hylander [284,285] show
that there are 40 tons of mercury in teeth with dental
amalgam of Swedish people, which results to the excre-
tion of 100 kg of mercury per year in wastewater. 1300
to 2200 tons of mercury in dental amalgam is present in
the teeth of citizens in the EU (27 countries) [284], and
for the USA the respective figures are about 1000 tons.
In the US, dental amalgam is the 3rd most significant
source of environmental mercury [286]. In contrast to
the EU, removed amalgam is not separated from the
wastewater of dental clinics in the US. But even in most
EU-countries, where such separators are in use, parts of
the dental amalgam leaks into the environment [284].
This mercury from dental amalgam (i.e. mercury
emissions from dental clinics in wastewater, excreted
mercury emissions from amalgam in living individuals,
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tissues of deceased and cremated humans with dental
amalgam) enter into the environment. When including
environmental costs into the economic calculation
(except costs from amalgam related diseases), amalgam
is the most costly dental material as was shown by
Hylander and Godsite [283].
The role of organized dentistry in SCENIHR and in
defending amalgam
The SCENIHR amalgam expert group consisted of one
engineer (chairman), four dentists, a toxicologist and
two veterinarians. The chairman has tight contacts to
the industry. No experts for medicine or environmental
medicine were included. One must wonder why it were
the dentists who represented the strongest party in
SCENIHR.
Due to their education and clinical experience, dentist
are not able to judge medical systemic adverse side
effects caused by dental amalgam, like multiple sclerosis,
autism, autoimmunity, Alzheimer’s disease, psychiatric
diseases etc. Usage of dental amalgam may increase
worldwide (increasing caries epidemic in undeveloped
countries which constitute the highest percentage of the
world`s population ). Today, dental organisations are
t h eo n l yt r a d eg r o u po fh e a l t hp r o f e s s i o n a l sw h o
endorse the use of a product that is primarily made of
mercury. Every amalgam patent has been produced
according to dental organisations specifications
[287,288]. This may indeed be a critical point, because
organized dentistry, which has always support the use of
dental amalgam, are responsible for adverse side effects
[287,288]. Therefore, the strategies of organized dentis-
try used to influence science and politics over the last
decades [287-290] may be analogous to other well
known topics with existing conflicts of interest, where
effective measures have been applied to influence
science and politics regarding dangerous products
[291-295].
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